Reference number(s)
2897-H

Quantity Limit
Buprenorphine Sublingual Tablets

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name	Dosage Form
buprenorphine (brand unavailable)	buprenorphine	sublingual tablets

Indications

FDA-approved Indications

Buprenorphine Sublingual Tablets are indicated for the treatment of opioid dependence and are preferred for induction. Buprenorphine Sublingual Tablets should be used as part of a complete treatment plan to include counseling and psychosocial support.

Initial Limit Quantity

This limit is coded for daily dose. Limits do not accumulate together. Patient is allowed the maximum limit for each drug and strength.

Drug	Daily Limit
Buprenorphine Sublingual Tablet 2 mg	3 units / day
Buprenorphine Sublingual Tablet 8 mg	3 units / day

References

1. Buprenorphine sublingual tablets [package insert]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc.; September 2023.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed November 5, 2024.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 11/05/2024).
4. Cunningham C, Edlund MJ, Fishman M, et al. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 focused update. American Society of Addiction Medicine. January 2020. 1-91.

Document History

Written by: UM Development (CF/DS)

Date Written: 03/2019

Revised: (CF) 11/2019 (opioid dependence updated to opioid use disorder); (DS) 11/2020 (changed from QvT to DD), 11/2021 (no clinical changes); (DRS) 11/2022 (no clinical changes), (DFW) 11/2023 (no clinical changes), 11/2024 (no clinical changes)

Reviewed: Medical Affairs: (DNC) 03/2019; (CHART) 11/27/2019, 12/03/2020, 12/02/2021, 12/01/2022, 11/30/2023, 11/21/2024

External Review: 08/2019, 02/2020, 02/2021, 02/2022, 03/2023, 02/2024, 02/2025